Supersensitivity Psychosis with Acute Dystonia.

antipsychotic withdrawal dopamine dopamine supersensitivity dystonia electroconvulsive therapy (ECT) olanzapine schizoaffective disorder schizophrenia supersensitivity psychosis

Journal

HCA healthcare journal of medicine
ISSN: 2689-0216
Titre abrégé: HCA Healthc J Med
Pays: United States
ID NLM: 9918316187606676

Informations de publication

Date de publication:
2023
Historique:
medline: 10 7 2023
pubmed: 10 7 2023
entrez: 10 7 2023
Statut: epublish

Résumé

Supersensitivity psychosis is a phenomenon that occurs with chronic usage of antipsychotics secondary to treatment resistance. At this time, there are no standardized guidelines regarding the management of supersensitivity psychosis. We present a case of a patient with schizoaffective disorder who developed supersensitivity psychosis and acute dystonia in response to discontinuing psychotropic medications, including high-dose quetiapine and olanzapine. The patient presented with excessive anxiety, paranoia, bizarre thoughts, and generalized dystonia affecting the face, trunk, and extremities. We treated the patient with olanzapine, valproic acid, and diazepam, which alleviated the psychosis back to baseline and significantly improved the dystonia. Despite compliance, the patient returned for inpatient stabilization due to depressive symptoms and worsening of the dystonia. During the second admission, the patient required further modification of psychotropics and supplemental electroconvulsive therapy. In this paper, we discuss the proposed treatment of supersensitivity psychosis, including the role that electroconvulsive therapy may play in alleviating supersensitivity psychosis and associated movement disorders. We hope to expand the knowledge of additional neuromotor manifestations in supersensitivity psychosis and the management of this unique presentation.

Identifiants

pubmed: 37426559
doi: 10.36518/2689-0216.1465
pii: 26890216_01042023_57
pmc: PMC10327954
doi:

Types de publication

Case Reports

Langues

eng

Pagination

57-60

Informations de copyright

© 2023 HCA Physician Services, Inc. d/b/a Emerald Medical Education.

Déclaration de conflit d'intérêts

Conflicts of Interest The authors declare that they have no conflicts of interest.

Références

Psychother Psychosom. 2017;86(4):189-219
pubmed: 28647739
Clin Psychopharmacol Neurosci. 2020 May 31;18(2):331-336
pubmed: 32329314
Ther Adv Psychopharmacol. 2017 Mar;7(3):113-117
pubmed: 28348731
Curr Neuropharmacol. 2017;15(1):174-183
pubmed: 27264948
Handb Clin Neurol. 2019;165:415-428
pubmed: 31727227
Psychother Psychosom. 2019;88(5):313-314
pubmed: 31291629
Neuropsychiatr Dis Treat. 2014 Jul 03;10:1209-12
pubmed: 25061306
Noro Psikiyatr Ars. 2016 Jun;53(2):178-180
pubmed: 28360793

Auteurs

Tatiana Nunez (T)

UCF/HCA Healthcare Graduate Medical Education Consortium, Psychiatry Residency Program, Orlando, FL.
HCA Florida Osceola Hospital, Kissimmee, FL.

Gabriella Meyerson (G)

UCF/HCA Healthcare Graduate Medical Education Consortium, Psychiatry Residency Program, Orlando, FL.
HCA Florida Osceola Hospital, Kissimmee, FL.

Mays Alani (M)

HCA Florida Osceola Hospital, Kissimmee, FL.
UCF/HCA Healthcare Graduate Medical Education Consortium, Neurology Residency Program, Orlando, FL.

Shahid Elahi (S)

UCF/HCA Healthcare Graduate Medical Education Consortium, Psychiatry Residency Program, Orlando, FL.
HCA Florida Osceola Hospital, Kissimmee, FL.

Enrique Vargas (E)

UCF/HCA Healthcare Graduate Medical Education Consortium, Psychiatry Residency Program, Orlando, FL.
HCA Florida Osceola Hospital, Kissimmee, FL.

Classifications MeSH